SynthesisBJU international2026
Secondary leukaemia after testicular germ cell tumour treatment: a systematic review and meta-analysis.
Synthesis in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTesticular germ cell tumours (TGCTs) are the most common malignancy in men aged 15-35 years. Management options for men with TGCTs include surgery, radiation and/or chemotherapy, depending on stage. Given TGCTs' excellent survival, most patients live long enough to experience delayed treatment toxicities, warranting careful consideration of therapeutic decisions. An important outcome of interest is the development of secondary leukaemia.
methodsA systematic literature search was conducted through a combination of database searches (MEDLINE, EMBASE, and Cochrane library) and manual review. Studies evaluating the incidence of secondary malignant neoplasms in patients following treatment for TGCTs were identified. Our primary outcome was the diagnosis of any leukaemia following treatment, compared to the general population. Meta-analyses were performed using random-effects models, with outcomes reported as standardised incidence ratios (SIRs). Strength of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.
resultsSix studies including 57 365 patients with 163 secondary leukaemias were included. The weighted-mean follow-up was 12.8 years. The incidence of leukaemia following definitive treatment of TGCTs varied by treatment modality. Chemotherapy was associated with an increase in risk (SIR 5.77, 95% confidence interval [CI] 1.35-24.62; P = 0.03), whereas radiation showed no statistically significant association (SIR 2.55, 95% CI 0.70-9.32; P = 0.11). The certainty of evidence was graded as moderate using the GRADE framework.
conclusionsChemotherapy is associated with an increase in the relative risk of secondary leukaemias after treatment of TGCTs, although the absolute risk remains small.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.